SAB BIOTHERAPEUTICS, INC. Accounts Payable and Other Accrued Liabilities, Current
SAB BIOTHERAPEUTICS, INC. (SABS) had Accounts Payable and Other Accrued Liabilities, Current of $7.21 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $7.21M.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $5.39M.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $6.58M; Accounts Payable and Other Accrued Liabilities, Current as first filed $6.58M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $6.85M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current | Accounts Payable and Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.21M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $5.39M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $6.58M 10-Q · filed 2026-08-06 | $6.58M 10-K · filed 2026-03-09 |
| 2025-09-30 | $6.85M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $7.09M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $6.06M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $5.47M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $6.88M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $5.05M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $5.17M 10-Q · filed 2024-05-20 | |
| 2023-12-31 | $6.69M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $5.30M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $5.93M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | $8.19M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $9.92M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $10.24M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $9.86M 10-K · filed 2023-04-14 | |
| 2022-03-31 | $11.86M 10-K · filed 2023-04-14 | |
| 2021-12-31 | $12.46M 10-K/A · filed 2023-04-28 | |
| 2020-12-31 | $1.90M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |